HK1052874B - 萘二甲醯亞胺組成物以及其用途 - Google Patents

萘二甲醯亞胺組成物以及其用途

Info

Publication number
HK1052874B
HK1052874B HK03105124.5A HK03105124A HK1052874B HK 1052874 B HK1052874 B HK 1052874B HK 03105124 A HK03105124 A HK 03105124A HK 1052874 B HK1052874 B HK 1052874B
Authority
HK
Hong Kong
Prior art keywords
agents
naphthalimide
antiproliferative agent
antiproliferative
host
Prior art date
Application number
HK03105124.5A
Other languages
English (en)
Other versions
HK1052874A1 (en
Inventor
Dennis M Brown
Original Assignee
Chemgenex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemgenex Pharmaceuticals Inc filed Critical Chemgenex Pharmaceuticals Inc
Publication of HK1052874A1 publication Critical patent/HK1052874A1/xx
Publication of HK1052874B publication Critical patent/HK1052874B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
HK03105124.5A 2000-04-12 2003-07-15 萘二甲醯亞胺組成物以及其用途 HK1052874B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19710300P 2000-04-12 2000-04-12
PCT/US2001/012169 WO2001078705A2 (en) 2000-04-12 2001-04-12 Compositions containing a naphthalmide and an antiproliferative agent

Publications (2)

Publication Number Publication Date
HK1052874A1 HK1052874A1 (en) 2003-10-03
HK1052874B true HK1052874B (zh) 2006-05-04

Family

ID=22728064

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03105124.5A HK1052874B (zh) 2000-04-12 2003-07-15 萘二甲醯亞胺組成物以及其用途

Country Status (10)

Country Link
US (2) US6630173B2 (zh)
EP (1) EP1274458B1 (zh)
JP (1) JP2003530431A (zh)
AT (1) ATE305312T1 (zh)
AU (1) AU5348301A (zh)
CA (1) CA2404278C (zh)
DE (1) DE60113666T2 (zh)
ES (1) ES2248312T3 (zh)
HK (1) HK1052874B (zh)
WO (1) WO2001078705A2 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734178B2 (en) * 2000-03-15 2004-05-11 Chemgenex Therapeutics, Inc. Cephalotaxine alkaloid compositions and uses thereof
DE60113666T2 (de) * 2000-04-12 2006-06-14 Chemgenex Pharmaceuticals Inc Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten
US20060211648A1 (en) * 2000-04-12 2006-09-21 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US7135481B2 (en) * 2000-04-12 2006-11-14 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US20050170015A1 (en) * 2000-10-31 2005-08-04 Brown Dennis M. Antiproliferative colchicine compositions and uses thereof
US20050239816A1 (en) * 2002-04-22 2005-10-27 Xanthus Life Sciences, Inc. Amonafide salts
US6693198B2 (en) 2002-04-22 2004-02-17 Xanthus Life Sciences, Inc. Amonafide salts
AU2003221767B2 (en) * 2002-04-24 2008-07-31 Research Development Foundation Synergistic effects of nuclear transcription factor NF-kB inhibitors and anti-neoplastic agents
JP2005533088A (ja) * 2002-07-08 2005-11-04 ケムジェネックス・ファーマシューティカルズ・リミテッド アモナフィドを含むナフタルイミドの製造およびその医薬製剤
JP2006501199A (ja) * 2002-07-17 2006-01-12 ケムジェネックス・ファーマシューティカルズ・リミテッド ホモハリングトニンを含むセファロタキシンの製剤および投与方法
US7642252B2 (en) * 2002-07-22 2010-01-05 Chemgenex Pharmaceuticals, Inc. Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
JP2007525214A (ja) * 2004-01-30 2007-09-06 ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド Ｎ−アセチルトランスフェラーゼ遺伝子型解析によって投与するナフタルイミド
JP2008501719A (ja) * 2004-06-04 2008-01-24 ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド ナフタルイミドおよびｐａｒｐ−１インヒビターを使用する細胞増殖性疾患の処置方法
US20060193893A1 (en) * 2005-02-10 2006-08-31 Chemgenex Pharmaceuticals, Inc. Medical devices
KR101506607B1 (ko) * 2007-04-13 2015-03-30 켐제닉스 파마슈티칼스 인크. 세팔로탁신 경구 제형

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183821A (en) * 1983-09-19 1993-02-02 Laboratories Knoll, S.A. Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors
US5420137A (en) 1989-07-11 1995-05-30 Knoll Ag Amonafide salts
FR2673944B1 (fr) * 1991-03-13 1995-03-10 Sanofi Elf Derives de l'1,8-naphtalimide, leur procede de preparation et les compositions pharmaceutiques les contenant.
EP1019034A2 (en) * 1997-07-01 2000-07-19 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
US6734178B2 (en) * 2000-03-15 2004-05-11 Chemgenex Therapeutics, Inc. Cephalotaxine alkaloid compositions and uses thereof
CA2403490A1 (en) * 2000-03-21 2001-10-25 Atherogenics, Inc. N-substituted dithiocarbamates for the treatment of biological disorders
DE60113666T2 (de) * 2000-04-12 2006-06-14 Chemgenex Pharmaceuticals Inc Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten

Also Published As

Publication number Publication date
ES2248312T3 (es) 2006-03-16
DE60113666D1 (de) 2005-11-03
US6630173B2 (en) 2003-10-07
CA2404278A1 (en) 2001-10-25
US20040047918A1 (en) 2004-03-11
WO2001078705A3 (en) 2002-06-20
EP1274458A2 (en) 2003-01-15
HK1052874A1 (en) 2003-10-03
ATE305312T1 (de) 2005-10-15
DE60113666T2 (de) 2006-06-14
CA2404278C (en) 2010-03-23
WO2001078705A2 (en) 2001-10-25
US20020025916A1 (en) 2002-02-28
EP1274458B1 (en) 2005-09-28
AU5348301A (en) 2001-10-30
JP2003530431A (ja) 2003-10-14

Similar Documents

Publication Publication Date Title
HK1052874A1 (en) Compositions containing a naphthalmide and an antiproliferative agent
HK1054967A1 (en) Method of amplifying nucleic acid by using double-stranded nucleic acid as template
AU7878301A (en) Method of amplifying nucleic acid
AU4580301A (en) Cephalotaxine alkaloid compositions and uses thereof
ATE425165T1 (de) Verfahren zur zubereitung von inhibitoren des nukleosid-metabolismus
EP1537227A4 (en) METHOD FOR EFFECTIVE RNA INTERFERENCE IN SUGAR CELLS
WO2000072799A3 (en) Method and compositions for treating the inflammatory response
CA2400554A1 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
AP2001002319A0 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
AU2001278783A1 (en) Method of amplifying nucleic acid
PL334561A1 (en) Novel phtalysinones
HK1068375A1 (en) Method of determining dihydropyrimidine dehydrogenase gene expression
WO2001004357A3 (en) Generic sbe-fret protocol
NZ524559A (en) 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
PT1075477E (pt) Novos n-oxidos de benzonaftiridina
AU2003280603A8 (en) Method of amplifying nucleic acid
HK1040769A1 (en) Method for detection and quantification of specific nucleic acid.
EP1432725A4 (en) RNA INTERFERENCE-MEDIATED INHIBITION OF TELOMERASEGENEXPRESSION WITH SHORT INTERFERING NUCLEIC ACID (SINA)
AU2003213057A8 (en) Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
WO2007095639A3 (en) Napht alimide compositions and uses thereof
WO2001091740A3 (en) Compositions containing naphthaquinone and an antiproliferative agent
DE60323267D1 (en) Rna-bioassay
EP1499628A4 (en) MEDIATED INHIBITION OF RNA INTERFERENCE OF STEAROYL-COA DESATURASE GENE EXPRESSION (SCD) USING SHORT INTERFERENCE NUCLEIC ACIDS
WO2001080842A3 (en) Compositions comprising a methylnogarol in combination with an antiproliferative agent
AU5247000A (en) Method for eliminating nucleic acid amplification inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120412